Objective: Carotid endarterectomy (CEA) is a procedure performed by both vascular surgeons and neurosurgeons in the UK. We present a single neurosurgeon's experience of 728 CEAs over 25 years, performed under both general and local anesthesia, and discuss the results in this context. Our objective was to report on the efficacy of CEA in the hands of a neurosurgeon.
Methods: Prospective outcome data were collected for all patients who underwent CEA performed by the senior author (A.D.M.) from 1987 to 2011. Data evaluated included patient age, sex, surgical indication, preoperative characteristics, diagnostic modalities used, shunt usage, operative time, any neurological deterioration during or after surgery, and early postoperative problems. Outcome measures used were 30-day death and 30-day disabling stroke. The results were tabulated and analyzed using JMP 8.0.2 (SAS Inc., Cary, NC).
Results: The 30-day death rate was 0.8% and the 30-day disabling stroke rate was 1.7% in our series. The mean operative time was 135 minutes (±38.1), and the mean clamp time was 28.4 minutes (±8.5). In the subset of patients who had the operation performed under local anesthesia (n = 616), the disabling stroke rate was 1.6% and the death rate was 0.6%. In the subset of asymptomatic patients (n = 194), the 30-day death and 30-day disabling stroke rates were each 1%. Postoperative complications were uncommon.
Conclusions: According to our data, CEA under local anesthesia is safe procedure in the hands of a neurosurgeon and would be recommended according to the clinical presentation and local guidelines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.wneu.2013.02.088 | DOI Listing |
BMJ
January 2025
Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Objective: To assess whether intra-arterial tenecteplase administered after successful endovascular recanalisation improves outcomes in patients with acute arterial occlusion of the posterior circulation.
Design: Multicentre randomised controlled trial.
Setting: 31 hospitals in China, 24 January 2023 to 24 August 2023.
J Clin Neurosci
January 2025
Comprehensive Centre for Stroke Care, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala 695011, India. Electronic address:
Background: The QT interval in ECG is susceptible to autonomic fluctuations, a known occurrence in acute ischemic stroke (AIS). Previous research has highlighted QT interval changes between ischemic and haemorrhagic strokes. However, there is scarce literature on the differential effect of AIS subtypes on QT interval.
View Article and Find Full Text PDFJ Clin Invest
January 2025
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Ischemic stroke is a major cause of adult disability. Early treatment with thrombolytics and/or thrombectomy can significantly improve outcomes; however, following these acute interventions, treatment is limited to rehabilitation therapies. Thus, the identification of therapeutic strategies that can help restore brain function in the post-acute phase remains a major challenge.
View Article and Find Full Text PDFNeurol Sci
January 2025
Department of Neurology, Provincial Hospital of Bolzano (SABES- ASDAA), Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, 39100, Italy.
Introduction: Vortioxetine is a multimodal antidepressant with a high tolerability profile. Recent evidence suggests a role for vortioxetine in improving cognitive function and reducing functional disability linked to depression. We conducted a systematic review on the use of vortioxetine in different neurological disorders.
View Article and Find Full Text PDFStroke
January 2025
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China. (X.X., X.L., Y.P., Yufei Wei, Y.J., M.W., J.J., X.M., Yilong Wang, Yongjun Wang, L.L.).
Background: We performed a prespecified subgroup analysis of the CATIS-2 trial (China Antihypertensive Trial in Acute Ischemic Stroke II) to compare the effect of early versus delayed antihypertensive treatment on death and disability in patients with and without medical history of hypertension.
Methods: CATIS-2 is a multicenter randomized clinical trial conducted in 106 hospitals in China. The trial randomized 4810 patients with acute ischemic stroke within 24 to 48 hours of symptom onset and elevated systolic blood pressure between 140 and <220 mm Hg to receive antihypertensive treatment immediately after randomization or to discontinue antihypertensive medications for 7 days and then receive treatment on day 8.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!